
Pfizer and BioNTech hit back against CureVac suit over Covid-19 vaccine patents
After its Covid-19 vaccine candidate petered out, CureVac earlier this month filed suit against BioNTech in German court, stating that CureVac should be compensated for the alleged infringement of a range of patents.
However, BioNTech made clear that it is willing to go to the mat against CureVac, and it brought on its partner Pfizer in a Massachusetts court filing to counter what they see as groundless claims.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.